These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29596023)

  • 1. Inflammation-induced lymphatic architecture and bone turnover changes are ameliorated by irisin treatment in chronic inflammatory bowel disease.
    Narayanan SA; Metzger CE; Bloomfield SA; Zawieja DC
    FASEB J; 2018 Sep; 32(9):4848-4861. PubMed ID: 29596023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DSS-induced colitis produces inflammation-induced bone loss while irisin treatment mitigates the inflammatory state in both gut and bone.
    Metzger CE; Narayanan SA; Elizondo JP; Carter AM; Zawieja DC; Hogan HA; Bloomfield SA
    Sci Rep; 2019 Oct; 9(1):15144. PubMed ID: 31641205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory Bowel Disease in a Rodent Model Alters Osteocyte Protein Levels Controlling Bone Turnover.
    Metzger CE; Narayanan A; Zawieja DC; Bloomfield SA
    J Bone Miner Res; 2017 Apr; 32(4):802-813. PubMed ID: 27796050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A moderately elevated soy protein diet mitigates inflammatory changes in gut and in bone turnover during chronic TNBS-induced inflammatory bowel disease.
    Metzger CE; Narayanan SA; Zawieja DC; Bloomfield SA
    Appl Physiol Nutr Metab; 2019 Jun; 44(6):595-605. PubMed ID: 30352170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of emodin on inflammatory bowel disease-related osteoporosis.
    Luo JS; Zhao X; Yang Y
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31934719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of dihydroartemisinin on inflammatory bowel disease-related bone loss in a rat model.
    Ge X; Chen Z; Xu Z; Lv F; Zhang K; Yang Y
    Exp Biol Med (Maywood); 2018 May; 243(8):715-724. PubMed ID: 29763384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss.
    Zhang YL; Chen Q; Zheng L; Zhang ZW; Chen YJ; Dai YC; Tang ZP
    World J Gastroenterol; 2022 Apr; 28(13):1315-1328. PubMed ID: 35645540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hindlimb unloading causes regional loading-dependent changes in osteocyte inflammatory cytokines that are modulated by exogenous irisin treatment.
    Metzger CE; Anand Narayanan S; Phan PH; Bloomfield SA
    NPJ Microgravity; 2020; 6():28. PubMed ID: 33083525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigation of inflammatory bowel disease-related osteoporosis by oxyberberine: Insights into the RANKL/NF-κB signaling pathway.
    Chen T; Ai G; Liang G; Zeng L; Zhao D; Liu J; Dou Y
    Biomed Pharmacother; 2024 May; 174():116523. PubMed ID: 38574627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.
    Moschen AR; Kaser A; Enrich B; Ludwiczek O; Gabriel M; Obrist P; Wolf AM; Tilg H
    Gut; 2005 Apr; 54(4):479-87. PubMed ID: 15753532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphatic dysregulation in intestinal inflammation: new insights into inflammatory bowel disease pathomechanisms.
    Becker F; Yi P; Al-Kofahi M; Ganta VC; Morris J; Alexander JS
    Lymphology; 2014 Mar; 47(1):3-27. PubMed ID: 25109166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut, inflammation and osteoporosis: basic and clinical concepts.
    Tilg H; Moschen AR; Kaser A; Pines A; Dotan I
    Gut; 2008 May; 57(5):684-94. PubMed ID: 18408105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irisin inhibits osteocyte apoptosis by activating the Erk signaling pathway in vitro and attenuates ALCT-induced osteoarthritis in mice.
    He Z; Li H; Han X; Zhou F; Du J; Yang Y; Xu Q; Zhang S; Zhang S; Zhao N; Yan M; Yu Z
    Bone; 2020 Dec; 141():115573. PubMed ID: 32768686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6.
    Vetrano S; Borroni EM; Sarukhan A; Savino B; Bonecchi R; Correale C; Arena V; Fantini M; Roncalli M; Malesci A; Mantovani A; Locati M; Danese S
    Gut; 2010 Feb; 59(2):197-206. PubMed ID: 19846409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet interaction with lymphatics aggravates intestinal inflammation by suppressing lymphangiogenesis.
    Sato H; Higashiyama M; Hozumi H; Sato S; Furuhashi H; Takajo T; Maruta K; Yasutake Y; Narimatsu K; Yoshikawa K; Kurihara C; Okada Y; Watanabe C; Komoto S; Tomita K; Nagao S; Miura S; Hokari R
    Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G276-85. PubMed ID: 27313177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of lymphatic alterations in the pathogenesis and treatment of inflammatory bowel disease.
    Zhang L; Ocansey DKW; Liu L; Olovo CV; Zhang X; Qian H; Xu W; Mao F
    Biomed Pharmacother; 2021 Aug; 140():111752. PubMed ID: 34044275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteocytes reflect a pro-inflammatory state following spinal cord injury in a rodent model.
    Metzger CE; Gong S; Aceves M; Bloomfield SA; Hook MA
    Bone; 2019 Mar; 120():465-475. PubMed ID: 30550849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging roles of lymphatics in inflammatory bowel disease.
    Alexander JS; Chaitanya GV; Grisham MB; Boktor M
    Ann N Y Acad Sci; 2010 Oct; 1207 Suppl 1():E75-85. PubMed ID: 20961310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavokawain B inhibits NF-κB inflammatory signaling pathway activation in inflammatory bowel disease by targeting TLR2.
    Chen Y; Jin T; Zhang M; Hong B; Jin B; Hu C; Wang J; Chen Y; Zhang L; Wang Y; Huang L
    Toxicol Appl Pharmacol; 2024 May; 486():116922. PubMed ID: 38583725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.